Karamtara Engineering has set its Rs 875 crore IPO price band at Rs 241-254, with subscription opening September 9. The renewable energy and transmission products maker reported strong FY26 growth, while its diversified manufacturing portfolio supports expansion across global markets.
Motilal Oswal AMC is favouring high-growth themes including defence, renewables, hospitals, digital businesses and capital markets, while limiting exposure to large banks, IT, commodities, FMCG and traditional vehicles. Its concentrated, high-beta strategy targets sustained earnings growth and alpha.
Nifty faces continued bearish pressure after a fourth weekly decline, with 23,750-23,700 as crucial support and 24,150-24,200 resistance. Analysts expect volatility to stay subdued, while Bank Nifty remains range-bound. BSE, Groww and Angel One also await decisive breakouts for direction.
Nifty 50’s August 2026 stability historically signals significant volatility ahead. With future direction unclear, analysts advise shifting investment strategies toward earnings-led, stock-specific selections rather than broad index-level performance as the market faces potential near-term turbulence.
Ten BSE SmallCap stocks gained across all five sessions through September 4, outperforming a falling Sensex. The strongest performers delivered cumulative gains of up to 57%, highlighting resilience amid broader market weakness.
India’s IPO market is evolving beyond capital raising, with mutual funds, AIFs, insurers, global institutions and family offices driving deeper participation. Growing institutional selectivity highlights the need for sharper price discovery, better segmentation and a potential micro-cap category.
Ten stocks across autos, consumer technology, healthcare and financial services could benefit from stronger festive-season discretionary spending, supported by improving demand, product launches, operating leverage, credit growth and rising consumer activity.
Kashyap Javeri suggests India’s market valuation premium is misleading due to index concentration. He highlights strong mid- and small-cap earnings growth, reliable SIP inflows, and easing FPI selling, while cautioning against risks like rising crude prices and currency fluctuations.
Mukesh Ambani is pitching Jio Platforms as more than a telecom company ahead of its IPO, highlighting thousands of patents, AI and proprietary technology. But questions remain over the commercial value of its intellectual property and whether its technology ambitions justify a potential $120-140 billion valuation.
Fosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak, Axis, and ICICI Prudential Mutual Funds, while Gland Pharma shares closed higher at ₹2,932.40.
Warning! Information Posting in this website is only for educational purpose. We are not responsible for losses incurred in Trading based on this information.